 |
|
Monoamine Transporter Gene Polymorphisms and Antidepressant Response in Koreans With Late-Life Depression
Hyeran Kim, MD;
Shinn-Won Lim, MS;
Seonwoo Kim, PhD;
Jong-Won Kim, MD, PhD;
Yun Hee Chang, PhD;
Bernard J. Carroll, MB, PhD;
Doh Kwan Kim, MD, PhD
JAMA. 2006;296:1609-1618.
Context Polymorphisms in the serotonin transporter gene (5-HTT) may influence antidepressant response to selective serotonin reuptake inhibitors (SSRIs). The norepinephrine transporter (NET) is the analogous target for norepinephrine reuptake inhibitors (NRIs).
Objective To determine whether antidepressant responses to SSRIs or NRIs are associated with genetic polymorphisms of the corresponding monoamine transporters.
Design, Setting, and Patients A 6-week naturalistic treatment study with blinded outcome evaluation of 241 Korean inpatients and outpatients with major depression at an academic psychiatry service. Patients were recruited to the study from March 1998 through February 2003.
Interventions Treatment with an SSRI (fluoxetine or sertraline; n = 136) or an NRI (nortriptyline; n = 105) antidepressant. Adherence was assessed by measuring plasma concentration at 4 weeks. Patients were genotyped for s/l polymorphisms in 5-HTT promoter region (5-HTTLPR), 5-HTT intron 2 s/l variation, and NET G1287A variation of exon 9.
Main Outcome Measures An SSRI and NRI response (defined as  50% decrease in Hamilton Rating Scale for Depression score at 6 weeks).
Results NRI response was associated with the NET G1287A polymorphism (odds ratio [OR], 7.54; 95% confidence interval [CI], 2.53-22.49; P<.001). An SSRI response was associated with the 5-HTT intron 2 s/l variation (OR, 20.11; 95% CI, 4.27-94.74; P<.001). The 5-HTTLPR was also associated with an SSRI response (OR, 3.34; 95% CI, 1.41-7.91; P = .006). In contrast to studies in white patients, the favorable allele for SSRI response was S 5-HTTLPR. The S 5-HTTLPR was associated also with NRI response (OR, 3.73; 95% CI, 1.32-10.53; P = .01). The NET polymorphism was not associated with an SSRI response. The NET G1287A GG genotype (56% of the population) was associated with better response to the NRI (83.3% [35/42]) than to SSRI (58.7% [44/75]) (OR, 3.52; 95% CI, 1.39-8.95; P = .006). Some genotype combinations were associated with high rates of antidepressant response and others with low rates of response.
Conclusions Monoamine transporter gene polymorphisms were associated with response to antidepressants with homologous monoamine transporter targets. Combinations of polymorphisms were informative for response and nonresponse. Confirmation of these preliminary findings would permit refined pharmacogenetic selection of antidepressant treatment.
Author Affiliations: Departments of Psychiatry (Drs H. Kim and D. Kim) and Laboratory Medicine and Genetics (Dr J.-W. Kim), Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Center for Clinical Research (Ms Lim) and Biostatistics Unit (Dr S. Kim), Samsung Biomedical Research Institute, Seoul, Korea; Department of Food and Nutrition, Myongji University, Yongin, Korea (Dr Chang); and Pacific Behavioral Research Foundation, Carmel, Calif (Dr Carroll).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Moderation of antidepressant response by the serotonin transporter gene
Huezo-Diaz et al.
Br. J. Psychiatry 2009;195:30-38.
ABSTRACT
| FULL TEXT
Meta-analysis urges the development of new strategies to treat depression in order to improve cardiac prognosis: reply
Nicholson et al.
Eur Heart J 2007;28:1661-1662.
FULL TEXT
Pharmacogenomics in Psychiatry
Leckband et al.
Journal of Pharmacy Practice 2007;20:252-264.
ABSTRACT
Pharmacogenomics of Antidepressant Medications
Ehret
Journal of Pharmacy Practice 2006;19:342-352.
ABSTRACT
The Interface of Multiculturalism and Psychopharmacology
Rey
Journal of Pharmacy Practice 2006;19:379-385.
ABSTRACT
|
